Extended Data Table 1 Patients description

From: A phase 1 trial of adoptive transfer of vaccine-primed autologous circulating T cells in ovarian cancer

  1. Description of 18 patients enrolled in the study who received the treatment (although 19 patients were initially enrolled, only 18 were treated). Patient identification number, age, tumor histologic type, stage, number of prior chemotherapy lines (Ctx), number of vaccine (Vx) doses received pre-ACT, radiologic response by RECIST v1.1 at end of study of UPCC19809, days between previous treatment and ACT, number of T-cell infusions, number of vaccine doses received post-ACT, radiologic response by RECIST v1.1 and CA-125 response are reported.
Back to article page